Aker BioMarine
Aker BioMarine ASA is the world's leading supplier of Antarctic krill-derived ingredients, producing phospholipid omega-3 oils, proteins, and algae DHA for nutraceutical, pharmaceutical, aquaculture, and consumer health customers globally from its vertically integrated Antarctic-to-Houston supply chain.
- Company typePublic
- Founded2006
- HeadquartersOslo, Norway
- Headcount251–500
- GTM typeB2B and B2C
- OfferingHardware or Manufacturing
What Aker BioMarine does
Aker BioMarine ASA, founded in 2006 and listed on the Oslo Stock Exchange under ticker AKBM, is a Norwegian biotech innovator and the world's leading supplier of Antarctic krill-derived ingredients. The company operates a vertically integrated value chain from proprietary Eco-Harvesting vessels in the Southern Ocean, through a Montevideo logistics hub, to a Flexitech-based production facility in Houston, Texas, and a protein facility in Ski, Norway. Its technology base includes phospholipid extraction (PL+ platform), LPC-bound EPA/DHA delivery (Lysoveta, 40 patents in 16 countries), unmanned surface vehicles (Mariner USV), and a Cognite Data Fusion digital platform that has driven 56% unit cost reductions and 73% less downtime.
Aker BioMarine monetizes its krill and algae ingredients across four business segments: Human Health Ingredients (Superba Krill Oil, Lysoveta, FloraMarine, PL+ — B2B sales to nutraceutical manufacturers; $26.0M in Q1 2025, +16% YoY), Consumer Health Products (Kori Krill consumer brand, Lang Pharma Nutrition; $27.1M in Q1 2025, +4% YoY), Animal Feed (QRILL Aqua and QRILL Pet, partially divested in July 2024), and Emerging Business (Understory protein, AION circular economy, CaPre therapeutic, KRBNX biostimulants; $2.1M in Q1 2025). Revenue is generated primarily through B2B ingredient contracts, with distribution partnerships (Barentz in Europe, G.C. Chemie Pharmie in India, Function in China) and licensing/royalties (Trofi Nutritional for Lysoveta medical foods targeting Alzheimer's, male infertility, and gestational diabetes). Q1 2025 company revenue was USD 50.8M (+5% YoY) with adjusted EBITDA of USD 9.0M (+59%); 91% of turnover is from exports across more than 40 nationalities.
Aker BioMarine firmographics
Firmographics- Name
- Aker BioMarine
- Legal name
- Aker BioMarine ASA
- Website
- https://akerbiomarine.com
- Company type
- Public
- Founded year
- 2006
- Operating status
- Operating
- Headcount range
- 251–500 employees
- Short description
- Aker BioMarine ASA is the world's leading supplier of Antarctic krill-derived ingredients, producing phospholipid omega-3 oils, proteins, and algae DHA for nutraceutical, pharmaceutical, aquaculture, and consumer health customers globally from its vertically integrated Antarctic-to-Houston supply chain.
- Ownership category
- akta.pro rank
Aker BioMarine industry classification
Industry- Product category
- Marine-derived nutraceutical ingredients
- NAICS
- Aquaculture (1125)
- SIC
- Prepared Fresh Or Frozen Fish & Seafoods (2092)
- akta.pro primary industry
- Sustainable & Alternative-Protein Aquafeed (Insect, Algae, Single-Cell, Byproduct-Based) (AFADADAM)
- akta.pro secondary industries
- Aquaculture Feed & Nutrition (farm-level feed programs) (AFAEAAAL), Algae & Seaweed Proteins (Microalgae/Spirulina, Macroalgae) (AFAJAHAF)
Keywords
Where Aker BioMarine is headquartered
LocationHeadquarters
- HQ city
- Oslo
- HQ country
- Norway
- HQ region
- Europe
Offices5 records
Markets served
Aker BioMarine business model
Business model- GTM type
- B2B and B2C
- Offering type
- Hardware or Manufacturing
- Cost components
- Operations, Supply Chain, Personnel, Technology or R&D, Marketing or Sales, Infrastructure
Revenue model
- Human Health Ingredients: Sale of krill-derived ingredients (Superba Krill Oil, Lysoveta, FloraMarine, PL+) to nutraceutical and supplement manufacturers. Q1 2025 revenue of USD 26.0 million with 16% YoY growth. Nine consecutive quarters of revenue growth.
- Consumer Health Products: Sale of consumer-facing products including Kori Krill brand in US retail market, and Lang Pharma Nutrition products. Q1 2025 revenue of USD 27.1 million with 4% YoY growth.
- Animal Feed Ingredients: QRILL Aqua (aquaculture) and QRILL Pet (animal feed) product sales. Stable revenue with favorable developments in fish meal and fish oil markets.
- Emerging Business: Understory protein brand and other emerging ventures. Revenue of USD 2.1 million in Q1 2025, focused on reaching cash break-even.
- Licensing and Royalties: Licensing of Lysoveta intellectual property to Trofi Nutritional Inc. for medical foods targeting Alzheimer's disease, male infertility, and gestational diabetes. Royalty payments on sales.
Go-to-market motion3 records
Distribution channels7 records
Marketing channels6 records
Aker BioMarine product offering
Product offeringCore offering
Aker BioMarine harvests Antarctic krill using its proprietary Eco-Harvesting technology and converts it into krill oil, krill meal, and krill protein ingredients supplied to dietary supplement manufacturers, aquaculture feed companies, and pet food producers. The company also offers algae-derived DHA (Revervia) and a phospholipid-bound omega-3 ingredient (Lysoveta), markets a consumer-facing krill oil brand (Kori Krill Oil), and pursues emerging circular-economy applications such as AION and krill protein (Understory).
Product overview
Aker BioMarine offers a diversified portfolio of marine-based ingredients and consumer products organized across four business segments: Human Health Ingredients (Superba Krill Oil, Revervia algae DHA, LYSOVETA brain health, PL+ delivery technology, FloraMarine), Consumer Health Products (Kori Krill brand), Emerging Business (Understory protein, AION circular economy, CaPre therapeutic candidate, KRBNX agriculture biostimulants), and Animal Nutrition (QRILL Aqua for aquaculture, QRILL Pet for pet food). The company operates a fully transparent value chain from Antarctic krill harvesting through Montevideo logistics hub and Houston production facility to global customers in nutraceuticals, pharmaceuticals, aquaculture, and animal feed industries.
Differentiator
Problem solved
Functional benefit
Brands
- Superba Krill Oil: Natural source of essential omega-3s, phospholipids, choline and astaxanthin for human health
- Revervia
- Lysoveta
- PL+ Technology
- Understory
- AION
- Kori
- CaPre
- KRBNX
- FloraMarine
- QRILL Aqua
- QRILL Pet
Products and services
- Superba Krill Oil
- QRILL Aqua
- QRILL Pet
- Lysoveta
- Kori Krill Oil
- Revervia
- Understory
- AION
Quantifiable outcome
- 16% YoY revenue growth in Human Health Ingredients (Q1 2025)
- +4 more outcomes
Companies that use Aker BioMarine
Customer profileNamed customers6 records
Segments4 records
Ideal customer profiles4 records
Aker BioMarine technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
Aker BioMarine partnerships and signals
Strategic signalPartnerships
19 partnerships are on record, tiered core and minor.
- ENGIEcore24/7 renewable energy agreement enabling approximately 90% of electricity consumption at Houston facility to be matched hourly with local renewable generation from the Impact Solar Project in Lamar County, Texas. Supports sustainability goals and reduces Scope 2 emissions as part of 2030 carbon intensity reduction strategy. Facilitated by advisor Priority Power.
- Priority PowerminorServed as advisory partner in structuring the renewable energy transaction with ENGIE, helping align energy solutions with Aker BioMarine's sustainability priorities.
- Sustainable Markets Initiative (SMI)coreOcean Stewardship Initiative (OSI) developed in partnership with SMI, Aker BioMarine, Aker QRILL Company, and Marine Stewardship Council. Initial focus on Marine Protected Area covering 70% of Antarctic Peninsula. John Kerry appointed as Champion.
- Marine Stewardship CouncilcorePartnership for Ocean Stewardship Initiative focused on marine protection and science-based fisheries management. Supporting proposed Marine Protected Area covering 70% of Antarctic Peninsula.
- Academic Research InstitutionscorePartnership with academia on neurodegenerative disease prevention research.
- G.C. Chemie Pharmie Pvt. Ltd.coreStrategic distribution partnership to expand distribution of krill oil and algae-derived DHA ingredients across the Indian market. Part of India market expansion ahead of Vitafoods India 2026.
- Aker QRILL CompanycoreCCAMLR 2025 collaboration supporting Antarctic Peninsula MPA proposal. Joint participation at Clinton Global Initiative to promote Antarctic protection. Scale up circular partnership with AION.
- AIONcoreCircular partnership scaled up to reduce packaging waste. Agreement to transform over 3,000 pallets from used product bags into fully circular system, reducing plastic footprint and carbon emissions.
- Clinton Global InitiativeminorAker BioMarine and Aker QRILL Company participating to promote Antarctic MPA proposal at CGI Annual Meeting 2025.
- KGK Science Inc.coreClinical research organization engaged for Lysoveta clinical trial. Randomized, placebo-controlled trial enrolling 138 healthy adults aged 50-75 with mild memory complaints. Study to assess cognitive function, mood, omega-3 status, and BDNF levels over 112 days.
- Norwegian Board AssociationminorSponsorship and partnership to advance sports and inclusion. Aker BioMarine became main sponsor alongside VI Foundation.
- Barentz International B.V.coreDistribution agreement with global specialty ingredients solution provider for new marine ingredients in Europe.
- FunctioncoreStrategic partnership declaration with largest customer of Superba Krill oil in China. Includes intention for Function to license Kori brand in China and be first customer of Understory protein. Pursuing long-term strategic partnership for krill-based products.
- University of GlasgowcoreResearch partnership to investigate health benefits of krill oil and krill protein. Study led by university showed beneficial effects on skeletal muscle function and size.
- CognitecoreDigital transformation partnership using Cognite Data Fusion platform. 3 million data points contextualized, 56% unit cost reduction, 73% downtime reduction, 2x output improvement in Houston facility and Antarctic vessels.
- Microsoft NorwaycoreMoU signed to pursue joint innovation and co-sell opportunities within digital traceability of circular plastic products. Microsoft to help scale AION Loop platform globally using cloud and AI services.
- CSIROcoreCollaboration with Australia's national science agency on krill oil research. Joint winners of 2022 Nutra Ingredients Asia Award for osteoarthritis study.
- Trofi Nutritional Inc.coreLicensing agreement for Lysoveta intellectual property and supply. Trofi will invest in clinical trials targeting Alzheimer's disease, male infertility, and gestational diabetes, with royalty payments on sales. First medical food planned for 2024.
- Antarctic Wildlife Research Fund (AWR)coreUSD 1 million commitment over 5 years to support AWR's work on Antarctic ecosystem research. Fund established by Aker BioMarine, ASOC, and WWF-Norway in 2015. Has financed 20 research projects and 15 host institutions.
Scale indicators28 records
Recent moves11 records
Expansion highlights9 records
Aker BioMarine competitors and assessment
Company assessmentDirect peers
- KD Pharma Group: KD Pharma is a major manufacturer of omega-3 fatty acid concentrates and other lipid-based APIs and nutraceuticals. It competes with Aker BioMarine in the omega-3 ingredient space, though KD Pharma focuses more on fish oil concentrates versus Aker BioMarine's krill-derived phospholipid focus.
- Golden Omega: Golden Omega is a Chilean-based krill oil producer and direct competitor to Aker BioMarine, supplying krill oil ingredients for human nutrition supplements. They compete for the same B2B nutraceutical customers and are pursuing similar phospholipid-bound omega-3 positioning.
- BioMar: BioMar is one of the world's largest aquaculture feed manufacturers and a direct customer/competitor to Aker BioMarine's QRILL Aqua business. Both supply high-performance feeds for salmon, shrimp, and other farmed seafood, with BioMar representing a major channel for krill meal inclusion.
- Rimfrost: Rimfrost is a direct competitor in krill oil harvesting and ingredient production, sourcing from Antarctic waters. Like Aker BioMarine, it supplies krill-derived omega-3 phospholipid ingredients to nutraceutical manufacturers globally, making it the closest head-to-head competitor in the core krill oil market.
Broad incumbents
- DSM-Firmenich: DSM-Firmenich is a global science-based company in nutrition, health, and beauty, with a major presence in omega-3 ingredients (including the Veramaris JV), animal nutrition, and food ingredients. It is a broad incumbent that competes across multiple Aker BioMarine segments including aquaculture feed and supplement ingredients.
- Skretting (Nutreco): Skretting is the global aquaculture feed business of Nutreco and a dominant incumbent in fish and shrimp feed markets. It competes with Aker BioMarine in the aquaculture feed value chain and is a key potential customer for QRILL Aqua krill meal as an ingredient.
- Cargill: Cargill is one of the world's largest agricultural and food ingredient companies with significant presence in animal nutrition (including Cargill Aqua Nutrition) and plant-based omega-3 (via its partnership with BASF on algal DHA). It represents a broad incumbent competitor across Aker BioMarine's human health and animal feed segments.
- ADM Animal Nutrition: ADM is a global leader in human and animal nutrition with a major animal feed business. It is a broad incumbent that competes with Aker BioMarine's QRILL Pet and QRILL Aqua products in the animal nutrition segment, while also providing competing plant-based protein ingredients to the broader market.
Emerging players
- Checkerspot: Checkerspot is a biotechnology company producing novel oils and ingredients from microalgae, with applications in nutrition, personal care, and food. It represents an emerging competitor in the algae-based omega-3 and specialty lipid space, challenging Aker BioMarine's premium positioning with novel production methods.
- Veramaris: Veramaris is a DSM/Evonik joint venture producing algae-based EPA and DHA for aquaculture and human nutrition. It represents the main alternative to krill-derived omega-3 and competes with Aker BioMarine in both supplement and aquaculture feed markets with a vegan-friendly positioning.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Aker BioMarine social profiles
Digital presenceAker BioMarine compliance and trust
Trust signalCompliance7 records
Aker BioMarine financial estimates
Financial estimateRevenue estimate
Valuation estimate
Aker BioMarine leadership team
Management profileNumber of profiles
Aker BioMarine subsidiaries and ownership
Company hierarchySubsidiaries5 records
Aker BioMarine funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Aker BioMarine M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Aker BioMarine
What does Aker BioMarine do?
Aker BioMarine harvests Antarctic krill using its proprietary Eco-Harvesting technology and converts it into krill oil, krill meal, and krill protein ingredients supplied to dietary supplement manufacturers, aquaculture feed companies, and pet food producers. The company also offers algae-derived DHA (Revervia) and a phospholipid-bound omega-3 ingredient (Lysoveta), markets a consumer-facing krill oil brand (Kori Krill Oil), and pursues emerging circular-economy applications such as AION and krill protein (Understory).
Is Aker BioMarine a public or private company?
Aker BioMarine is a public company. It is classified as public and is currently operating.
When was Aker BioMarine founded?
Aker BioMarine was founded in 2006. It employs 251 to 500 people.
Where is Aker BioMarine based?
Aker BioMarine is headquartered in Oslo, Norway, in the Europe region.
How does Aker BioMarine make money?
Five revenue lines are on record. Human Health Ingredients are the primary driver. The others are consumer Health Products, animal Feed Ingredients, emerging Business and licensing and Royalties.
Who are Aker BioMarine's main competitors?
Direct peers on record are KD Pharma Group, Golden Omega, BioMar and Rimfrost. Broad incumbents are DSM-Firmenich, Skretting (Nutreco), Cargill and ADM Animal Nutrition. Emerging players are Checkerspot and Veramaris.
Does Aker BioMarine have an API?
No public API is recorded for Aker BioMarine.
What industry is Aker BioMarine in?
Aker BioMarine's product category is Marine-derived nutraceutical ingredients. Its primary akta.pro industry code is AFADADAM, Sustainable & Alternative-Protein Aquafeed (Insect, Algae, Single-Cell, Byproduct-Based), with a secondary code of AFAEAAAL, Aquaculture Feed & Nutrition (farm-level feed programs). Its NAICS code is 1125 and its SIC code is 2092.